Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Mylotarg added to intensive chemotherapy in adults with intermediate-risk acute myeloid leukemia
2007-001209-64Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- May 2007
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by CHU de Nantes. Primary endpoint: 3-year event-free survival. Started May 2007; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-001209-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001209-64.